Table 1.

Baseline patient characteristics.

	Maintenance therapy regimen
Variable	Cetuximab	Bevacizumab		All
	n = 79 (55.2%)	n = 64 (44.8%)	P-value	n = 143 (100%)
Gender			0.24
Female	27 (34.2%)	28 (43.8%)		55(38.5%)
Male	52 (65.8%)	36 (56.3%)		88 (61.5%)
Age at maintenance, median (range)	62.0 (21.0–90.0)	61.0 (24.0–76.0)	0.70	62.0 (21.0–90.0)
Smoking			0.21
Yes	34 (43.0%)	21 (32.8%)		55 (38.5%)
No	45 (57.0%)	43 (67.2%)		88 (61.5%)
Primary tumor site			0.01
Right colon	11 (13.9%)	24 (37.5%)		35 (24.5%)
Left colon	68 (86.1%)	40 (62.5%)		108 (75.5%)
Number of metastatic sites at start of maintenance therapy			0.16
0	0 (0.0%)	2 (3.1%)		2 (1.4%)
1	35 (44.3%)	18 (28.1%)		53 (37.1%)
2	28 (35.4%)	25 (39.1%)		53 (37.1%)
≥3	14 (17.7%)	16 (25.0%)		30 (21.0%)
Unknown	2 (2.5%)	3 (4.7%)		5 (3.5%)
Metastatic time			0.49
Synchronous	51 (64.6%)	39 (60.9%)		90 (62.9%)
Metachronous	26 (32.9%)	25 (39.1%)		51 (35.7%)
Unknown	2 (2.5%)	0 (0.0%)		2 (1.4%)
Preoperative chemotherapy			0.10
Yes	20 (25.3%)	9 (14.1%)		29 (20.3%)
No	59 (74.7%)	55 (85.9%)		114 (79.7%)
Surgical resection of primary tumor			0.16
Yes	59 (74.7%)	54 (84.4%)		113 (79.0%)
No	20 (25.3%)	10 (15.6%)		30 (21.0%)
Surgical resection of metastatic sites			0.83
Yes	26 (32.9%)	20 (31.3%)		46 (32.2%)
No	53 (67.1%)	44 (68.8%)		97 (67.8%)
Simultaneous resection			0.80
Yes	10 (12.7%)	10 (15.6%)		20 (14.0%)
No	68 (86.1%)	54 (84.4%)		122 (85.3%)
Unknown	1 (1.3%)	0 (0.0%)		1 (0.7%)
Line of maintenance therapy initiated			0.68
1	34 (43.0%)	23 (35.9%)		57 (39.9%)
2	31 (39.2%)	29 (45.3%)		60 (42.0%)
≥3	14 (17.7%)	12 (18.8%)		26 (18.1%)

simultaneous resection refers to whether metastases and primary tumor site are simultaneously resected.